The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor agonist. The active control is irbesartan. This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 12 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 150 study centers, globally.